Holders — by stockHoldings — by fund
Eagle Health Investments LP
Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-09-30 · filed with the SEC up to 45 days after quarter end · CIK 0001842545
$608.5M
disclosed book value
22
positions
12.1%
largest position share
Positions, as of 2026-09-30
top 23 of 22 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held
| # | Issuer | Shares | Value | % of book |
|---|---|---|---|---|
| 1 | ARGXARGENX SE | 76,593 | $73.4M | 12.1% |
| 2 | GHGUARDANT HEALTH INC | 300,685 | $53.6M | 8.8% |
| 3 | ICLRICON PUB LTD CO | 264,810 | $45.0M | 7.4% |
| 4 | ISRGINTUITIVE SURGICAL INC | 108,546 | $44.1M | 7.3% |
| 5 | UTHRUNITED THERAPEUTICS CORP DEL | 79,678 | $43.2M | 7.1% |
| 6 | INSMINSMED INC | 358,702 | $40.9M | 6.7% |
| 7 | PTGXPROTAGONIST THERAPEUTICS INC | 248,322 | $35.0M | 5.7% |
| 8 | ROIVROIVANT SCIENCES LTD | 879,191 | $32.2M | 5.3% |
| 9 | SRRKSCHOLAR ROCK HLDG CORP | 561,527 | $27.1M | 4.5% |
| 10 | ASNDASCENDIS PHARMA A/S | 118,629 | $27.0M | 4.4% |
| 11 | GHGUARDANT HEALTH INCPUT | 150,300 | $26.8M | 4.4% |
| 12 | CMPSCOMPASS PATHWAYS PLC | 2.1M | $25.6M | 4.2% |
| 13 | RVMDREVOLUTION MEDICINES INC | 120,346 | $24.7M | 4.1% |
| 14 | FTREFORTREA HLDGS INC | 1.2M | $23.6M | 3.9% |
| 15 | BSXBOSTON SCIENTIFIC CORP | 459,114 | $20.0M | 3.3% |
| 16 | KYMRKYMERA THERAPEUTICS INC | 119,268 | $13.3M | 2.2% |
| 17 | ALKSALKERMES PLC | 297,302 | $12.0M | 2% |
| 18 | AXSMAXSOME THERAPEUTICS INC. | 65,051 | $12.0M | 2% |
| 19 | DNTHDIANTHUS THERAPEUTICS INC | 131,344 | $11.6M | 1.9% |
| 20 | REPLREPLIMUNE GROUP INC | 724,787 | $9.6M | 1.6% |
| 21 | AVTXAVALO THERAPEUTICS INC | 235,093 | $3.6M | 0.6% |
| 22 | SMMTSUMMIT THERAPEUTICS INC | 154,493 | $2.6M | 0.4% |
| 23 | IMCRIMMUNOCORE HLDGS PLC | 46,300 | $1.4M | 0.2% |
Source: SEC Form 13F-HR, reporting period 2026-09-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.